Table 1.
ADEP study | DAVID study | |||
---|---|---|---|---|
Picotamide | Placebo | Picotamide | Aspirin | |
Dosage | 300 mg bid | 600 mg bid | 320 mg od | |
Clinical characteristics | ||||
n = 1150 | n = 1154 | n = 603 | n = 606 | |
Age | 63.4 + 7.3 | 62.9 + 7.4 | 63.8 + 7.2 | 64.6 + 7.3 |
Diabetes | 20% | 18% | 100% | 100% |
PAD | 100% | 100% | 100% | 100% |
Smoke | 39.6% | 37.1% | 30.5% | 28.4% |
Hypertension | 34.5% | 37.5% | 58.2% | 55.6% |
Dyslipidemia | 36.5% | 35.8% | 38% | 38.4% |
Previous stroke | 1.4% | 1.7% | 10.4% | 10.2% |
Coronary heart disease | 15% | 12.7% | 19.4% | 19% |
Side-effects | ||||
Gastro-intestinal | 11.1% | 12% | 10.9% | 18.3% |
Total | 14.3% | 13.5% | 25.6% | 33.9% |
Abbreviations: bid, twice a day; od, once a day; PAD, peripheral artery disease.